Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  2013-03-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1210/jc.2012-3930PMID 23533235
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Papillary thyroid microcarcinoma with fatal outcome: evidence of tumor progression in lymph node metastases: report of 3 cases, with morphological and molecular analysis.

  2013cited by this paper
• Papillary Microcarcinoma of the Thyroid: Clinical Characteristics and BRAFV600E Mutational Status of 977 Cases

  2013cited by this paper
• BRAFV600E Mutation in Papillary Thyroid Carcinoma: Significant Association with Node Metastases and Extra Thyroidal Invasion

  2012cited by this paper
• Runx2 isoform I controls a panel of proinvasive genes driving aggressiveness of papillary thyroid carcinomas.

  2012cited by this paper
• Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.

  2012cited by this paper
• The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.

  2012cited by this paper
• Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer?

  2012cited by this paper
• Oncogenic Alterations in Papillary Thyroid Cancers of Young Patients

  2012cited by this paper
• Reoperative central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: Efficacy, safety, and the association of the BRAF mutation

  2012cited by this paper
• BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis.

  2012cited by this paper
• A piece of the puzzle: what does BRAF status mean in the management of patients with papillary thyroid carcinoma?

  2012cited by this paper
• Immunohistochemical consistency between primary tumors and lymph node metastases of gastric neuroendocrine carcinoma

  2012cited by this paper
• Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?

  2012cited by this paper
• The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.

  2012cited by this paper
• BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas.

  2012cited by this paper
• BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma.

  2012cited by this paper
• BRAFV600E Mutation is Associated with Tumor Aggressiveness in Papillary Thyroid Cancer

  2012cited by this paper
• The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer

  2012cited by this paper
• Immunohistochemical Detection of the BRAF V600E-mutated Protein in Papillary Thyroid Carcinoma

  2012cited by this paper
• The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma.

  2012cited by this paper
• A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome.

  2012cited by this paper
• Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

  2012cited by this paper
• A High-Throughput Proteomic Approach Provides Distinct Signatures for Thyroid Cancer Behavior

  2011cited by this paper
• Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma

  2011cited by this paper
• The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases

  2011cited by this paper
• Inhibitor of DNA binding-1 induces mesenchymal features and promotes invasiveness in thyroid tumour cells.

  2011cited by this paper
• Role of BRAF in Thyroid Oncogenesis

  2011cited by this paper
• Papillary Thyroid Carcinomas with Cervical Lymph Node Metastases Can Be Stratified into Clinically Relevant Prognostic Categories Using Oncogenic BRAF, the Number of Nodal Metastases, and Extra-Nodal Extension

  2011cited by this paper
• The BRAF Mutation Is Predictive of Aggressive Clinicopathological Characteristics in Papillary Thyroid Microcarcinoma

  2010cited by this paper
• Thyroid cancer survival in the United States: observational data from 1973 to 2005.

  2010cited by this paper
• Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions.

  2010cited by this paper
• Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAFV600E mutation, clinicopathological features, and immunohistochemical findings

  2009cited by this paper
• BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients.

  2009cited by this paper
• Acquisition of BRAF gene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma

  2008cited by this paper
• BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.

  2008cited by this paper
• Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid

  2007cited by this paper
• Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.

  2007cited by this paper
• The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer

  2007cited by this paper
• Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.

  2006cited by this paper
• Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness

  2005cited by this paper
• High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes.

  2005cited by this paper
• No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan

  2005cited by this paper
• Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation.

  2005cited by this paper
• High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.

  2003cited by this paper
• BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC

  2003cited by this paper
• AJCC Cancer Staging Manual

  2002cited by this paper
• Molecular Genetic Changes in Metastatic Primary Barrett’s Adenocarcinoma and Related Lymph Node Metastases: Comparison with Nonmetastatic Barrett’s Adenocarcinoma

  2000cited by this paper

• Allele frequency in thyroid cancer: mechanisms, challenges, and applications in cancer therapy

  2025influential citation
• Association Between BRAF V600E Allele Frequency and Aggressive Behavior in Papillary Thyroid Microcarcinoma

  2025cites this paper
• Prognostication with Thyroid GuidePx in the context of tall cell variants.

  2024cites this paper
• Association of BRAF V600E allele frequency with clinicopathologic outcomes in papillary thyroid cancer.

  2024cites this paper
• Association of BRAF V600E Mutant Allele Proportion with the Dissemination Stage of Papillary Thyroid Cancer

  2024cites this paper
• Detection of the BRAFV600E Mutation in Circulating Free Nucleic Acids as a Biomarker of Thyroid Cancer: A Review

  2024cites this paper
• Genetic alterations and allele frequency of BRAF V600E and TERT mutation in papillary thyroid carcinoma with intermediate-to-high recurrence risk: a retrospective study

  2024cites this paper
• The Impact of BRAF V600E Mutation Allele Frequency on the Histopathological Characteristics of Thyroid Cancer

  2023cites this paper
• A Comparative Analysis of NOX4 Protein Expression in Malignant and Non-Malignant Thyroid Tumors

  2023cites this paper
• VAI TRÒ CỦA ĐỘT BIẾN BRAF V600E TRONG CARCINÔM TUYẾN GIÁP DẠNG NHÚ QUY ƯỚC

  2023influential citation
• Genetic and Clinicopathologic Characteristics of Papillary Thyroid Carcinoma in the Chinese Population: High BRAF Mutation Allele Frequency, Multiple Driver Gene Mutations, and RET Fusion May Indicate More Advanced TN Stage

  2022cites this paper
• Different Threshold of Malignancy for RAS-like Thyroid Tumors Causes Significant Differences in Thyroid Nodule Practice

  2022cites this paper
• OTT_A_339114 147..157

  2022cites this paper
• Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer With BRAF V600E Mutation

  2022cites this paper
• Cell-Free DNA Analysis within the Challenges of Thyroid Cancer Management

  2022cites this paper
• Combined Mutational and Clonality Analyses Support the Existence of Intra-Tumor Heterogeneity in Papillary Thyroid Cancer

  2021cites this paper
• Increased diagnostic sensitivity of palpation‐guided thyroid nodule fine‐needle aspiration cytology by BRAF V600E‐mutation analysis

  2021cites this paper
• Intratumoral Heterogeneity in Differentiated Thyroid Tumors: An Intriguing Reappraisal in the Era of Personalized Medicine

  2021cites this paper
• The ratio of BRAFV 600 E alleles can be used to assess the biological 1 behavior of papillary thyroid carcinoma

  2020cites this paper
• Intratumoral Genetic Heterogeneity in Papillary Thyroid Cancer: Occurrence and Clinical Significance

  2020cites this paper
• Langerhans cell histiocytosis of the thyroid together with papillary thyroid carcinoma

  2020cites this paper
• The ratio of BRAFV600E alleles can be used to assess the biological behavior of papillary thyroid carcinoma

  2020cites this paper
• BRAFV600E hot spot mutation in thyroid carcinomas: first Moroccan experience from a single-institution retrospective study

  2020cites this paper
• Progress in Microbes and Molecular Biology

  2020cites this paper
• A meta-analysis evaluating the relationship between B-type Raf kinase mutation and cervical lymphatic metastasis in papillary thyroid cancer

  2020cites this paper
• American College of Radiology thyroid imaging report and data system combined with K-RAS mutation improves the management of cytologically indeterminate thyroid nodules

  2019cites this paper
• The Combination of RET, BRAF and Demographic Data Identifies Subsets of Patients with Aggressive Papillary Thyroid Cancer

  2019cites this paper
• Dermoscopic similarity is an independent predictor of BRAF mutational concordance in multiple melanomas

  2019cites this paper
• Clinical significance of the BRAFV600E mutation in PTC and its effect on radioiodine therapy

  2019cites this paper
• Predictive Value of BRAFV600E Mutation for Lymph Node Metastasis in Papillary Thyroid Cancer: A Meta-analysis

  2018cites this paper
• Thyroid cancers of follicular origin in a genomic light: in-depth overview of common and unique molecular marker candidates

  2018cites this paper
• Tailored surgery according to molecular analysis in differentiated thyroid carcinomas.

  2018cites this paper
• Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?

  2017cites this paper
• The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma

  2017cites this paper
• Evaluation of molecular diagnostic approaches for the detection of BRAF p.V600E mutations in papillary thyroid cancer: Clinical implications

  2017cites this paper
• Clinical presentation and diagnosis of papillary thyroid cancer

  2017cites this paper
• Clinically significant sub-clonality for common drivers can be detected in 26% of KRAS/EGFR mutated lung adenocarcinomas

  2017cites this paper
• Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer

  2016cites this paper
• Staging of Thyroid Cancer

  2016cites this paper
• Vanishing tumors of thyroid: histological variations after fine needle aspiration.

  2016cites this paper
• A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer

  2016cites this paper
• Application of molecular biology of differentiated thyroid cancer for clinical prognostication.

  2016cites this paper
• Subclonality for BRAF Mutation in Papillary Thyroid Carcinoma Is Associated With Earlier Disease Stage.

  2016cites this paper
• Papillary Carcinoma: Clinical Aspects

  2016cites this paper
• Diagnostic potential of ancillary molecular testing in differentiation of benign and malignant thyroid nodules.

  2015cites this paper
• Association between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carcinoma.

  2015cites this paper
• BRAF Testing in Multifocal Papillary Thyroid Carcinoma

  2015cites this paper
• [Postoperative radioiodine ablation in patients with low risk differentiated thyroid carcinoma].

  2015cites this paper
• Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer

  2015cites this paper
• Real-Time PCR Cycle Threshold Values for the BRAFV600E Mutation in Papillary Thyroid Microcarcinoma May Be Associated With Central Lymph Node Metastasis

  2015influential citation
• TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.

  2015cites this paper
• A novel BRAF mutation in association with primary amelanotic melanoma with oral metastases

  2015cites this paper
• Postoperative radioiodine ablation in patients with low risk differentiated thyroid carcinoma

  2015cites this paper
• [Clinical guideline for management of patients with low risk differentiated thyroid carcinoma].

  2015cites this paper
• Ablación posquirúrgica con radioyodo en pacientes con carcinoma diferenciado de tiroides de bajo riesgo

  2015cites this paper
• Time to re‐consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma

  2015influential citation
• High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas.

  2014cites this paper
• How to use molecular testing results to guide surgery: a surgeon's perspective

  2014cites this paper
• High sensitivity analysis of BRAF mutations in neoplastic and non-neoplastic thyroid lesions

  2014cites this paper
• BRAF mutation status in papillary thyroid carcinoma: significance for surgical strategy

  2014cites this paper
• Langerhans Cell Histiocytosis of the Thyroid with Multiple Cervical Lymph Node Involvement Accompanying Metastatic Thyroid Papillary Carcinoma

  2014cites this paper
• Deep sequencing of KIT, MET, PIK3CA, and PTEN hotspots in papillary thyroid carcinomas with distant metastases.

  2014cites this paper
• Significance of Allelic Percentage of BRAF c.1799T > A (V600E) Mutation in Papillary Thyroid Carcinoma

  2014cites this paper
• Quantification of BRAF V600E alleles predicts papillary thyroid cancer progression.

  2014cites this paper
• Application of Molecular Diagnostics to the Evaluation of the Surgical Approach to Thyroid Cancer

  2014influential citation
• Update: the status of clinical trials with kinase inhibitors in thyroid cancer.

  2014cites this paper
• Detection of RAS mutation by pyrosequencing in thyroid cytology samples.

  2014cites this paper
• The prognostic significance of the BRAFV600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry

  2013cites this paper
• Should patients with papillary microcarcinoma undergo radioiodine ablation?

  2013cites this paper